Discovery of Artemin Molecule in Cats Provides New Biological Marker and Potential Treatment Target for Chronic Osteoarthritis Pain

NC State researchers identify the artemin molecule as a potential blood-test marker and treatment target for cats suffering from chronic joint disease pain.

By: AXL Media

Published: Mar 31, 2026, 3:59 AM EDT

Source: Information for this report was sourced from North Carolina State University

Mapping the Biological Commonalities of Chronic Pain

The underlying mechanisms of degenerative joint disease have long been documented in humans and dogs, but the specific biological pathways in felines remained largely a mystery. A new interdisciplinary study led by North Carolina State University has finally confirmed that cats share a key pain-signaling axis involving the molecule artemin and its receptor, GFRA-3. This pathway activates sensors in the spinal cord known as TRP ion channels, which are responsible for registering a wide spectrum of physical and chemical pain stimuli. By proving that this cellular sequence is conserved across species, researchers have opened a significant door for translating human and canine pain management strategies into feline medicine.

The Role of Artemin as a Diagnostic Indicator

The most practical breakthrough of the research is the correlation found between elevated levels of artemin in the blood and the physical presence of joint disease. By comparing more than 70 cats, the team discovered that those with radiographic evidence of osteoarthritis consistently displayed higher concentrations of artemin in their serum. This discovery provides a potential biological marker that could revolutionize how the disease is identified in clinical settings. According to Santosh Mishra, associate professor of neurobiology, utilizing a blood test for artemin could eventually replace the need for expensive and stressful X-rays, providing a faster and less invasive diagnostic route for aging pets.

Challenges in Assessing Feline Pain Perception

While the study established a strong link between artemin and the physical severity of joint disease, the researchers noted a complex discrepancy regarding pain levels. Interestingly, the concentration of artemin in the blood did not always correlate with the pain scores assessed by veterinarians during clinical exams. This highlights a persistent challenge in veterinary medicine: cats are notoriously adept at masking discomfort, making objective pain assessment difficult for human observers. To address this, the research team plans to integrate more objective technologies in future studies to better measure how these biological changes translate to the actual sensory experience of the animal.